Renal and cardiac function during alpha1-beta-blockade in congestive heart failure

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Congestive heart failure (CHF) involves kidney and neurohormonal systems.
• Standard CHF treatment includes diuretics, ACE inhibitors, and beta-blockers.
• Renal function monitoring is crucial during ACE inhibitor therapy for CHF.

Purpose of the Study:

• To evaluate if combined alpha1-beta-blockade (carvedilol) with diuretics and ACE inhibitors improves cardiac function without impairing renal function.
• To assess the impact of carvedilol on hemodynamics, cardiac function, and renal parameters in CHF patients.

Main Methods:

• Fourteen patients with moderate to severe CHF on diuretics and ACE inhibitors were studied.
• Carvedilol was administered for 4 months, followed by withdrawal.
• Measurements included cardiac function, blood pressure, heart rate, and renal function (GFR, renal blood flow, effective renal plasma flow).

Main Results:

• Carvedilol reduced blood pressure and heart rate, increasing ventricular ejection fractions.
• Cardiac output and pulmonary blood volume remained unchanged.
• Glomerular filtration rate (GFR) slightly decreased, but renal blood flow was stable and effective renal plasma flow increased.
• Plasma levels of angiotensin II and aldosterone were reduced.

Conclusions:

• Carvedilol enhances ACE inhibitor effects by lowering blood pressure and angiotensin II levels, and reducing heart rate.
• Cardiac adaptation occurred without altering cardiac output or pulmonary blood volume.
• Despite minimal renal changes, careful renal function monitoring is advised during carvedilol treatment in CHF patients.